Finch Therapeutics Group, Inc. (FNCHQ)
Finch Therapeutics Group, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $10.20, up 0.49% on the session, giving a market capitalisation of $16.4M. On trailing twelve-month figures it carries a trailing P/E of -1.18, a net margin of 0.0%. Its beta of 0.99 implies it has historically moved less than the broad market.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Finch Therapeutics Group, Inc. is most often compared with the following Healthcare names: